Also, medium-throughput screens for bioavailability are now possible with
rapid quantitation by LC–MS/MS techniques. These techniques will need to
continue to evolve to allow metabolism scientists the ability to keep pace with
the increasing speed of drug discovery. The increasing complexity of the
process will place an ever greater dependence on information management and
the ability to turn that information into knowledge will be tantamount. This is
especially true when one considers the advances in other fields of ADME-
related research, for example, transporters, interactions with nuclear hormone
receptors, that need to be characterized during the discovery of a drug. This
complexity ensures that the field of drug metabolism will continue to play an
increasing role in the endeavor to provide high quality drug candidates that
will become safe, highly efficacious medicines.
REFERENCES
Amacher DE. Reactive intermediates and the pathogenesis of adverse drug reactions:
the toxicology perspective. Curr Drug Metab 2006;7:219–229.
Anari MR, Baillie, TA. Bridging cheminformatic metabolite prediction and tandem
mass spectrometry. Drug Discov Today 2005;10:711–717.
Andrews CW, Bennett L, Yu LX. Predicting human oral bioavailability of a compound:
development of a novel quantitative structure-bioavailability relationship. Pharm
Res 2000;17:639–644.
Argoti D, Liang L, Conteh A, Chen L, Bershas D, Yu CP, Vouros P, Yang E. Cyanide
trapping of iminium ion reactive intermediates followed by detection and structure
identification using liquid chromatography–tandem mass spectrometry (LC–MS/
MS). Chem Res Toxicol 2005;18:1537–1544.
Baillie, TA. Future of toxicology-metabolic activation and drug design: challenges and
opportunities in chemical toxicology. Chem Res Toxicol 2006;19:889–893.
Balakin KV, Ivanenkov YA, Savchuk NP, Ivashchenko AA, Ekins S. Comprehensive
computational assessment of ADME properties using mapping techniques. Curr
Drug Discov Technol 2005;2:99–113.
Balani SK, Zhu T, Yang TJ, Liu Z, He B, Lee FW. Effective dosing regimen of 1-
aminobenzotriazole for inhibition of antipyrine clearance in rats, dogs, and monkeys.
Drug Metab Dispos 2002;30:1059–1062.
Buch H, Buzello W, Heymann E, Krisch, K. Inhibition of phenacetin- and acetanilide-
induced methemoglobinemia in the rat by the carboxylesterase inhibitor bis-[p-
nitrophenyl] phosphate. Biochem Pharmacol 1969;18:801–811.
Chen WG, Zhang C, Avery MJ, Fouda HG. Reactive metabolite screen for reducing
candidate attrition in drug discovery. Adv Exp Med Biol 2001;500:521–524.
Clader JW. The discovery of ezetimibe: a view from outside the receptor. J Med Chem
2004;47:1–9.
Cox KA, White RE, Korfmacher WA. Rapid determination of pharmacokinetic pro-
perties of new chemical entities:in vivoapproaches. Comb Chem High Throughput
Screen 2002;5:29–37.
254 DRUG METABOLISM RESEARCH